Jonathan Corren, MD / Mario Castro, MD - Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment

This content has been developed for healthcare professionals only.
Patients who seek health information should consult with their
physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides,
and complete CME/MOC/AAPA information, and to apply for credit,
please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will
be available until December 18, 2024.


Beyond Airway Inflammation: Examining the Potential Clinical
Utility of Mucus Plugging and Airway Hyperresponsiveness in
Severe Asthma to Assess Severity and Guide Biologic Treatment


In support of improving patient care, PVI, PeerView Institute for
Medical Education, is jointly accredited by the Accreditation
Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the
American Nurses Credentialing Center (ANCC), to provide
continuing education for the healthcare team.


SupportThis activity is supported by an
independent educational grant from AstraZeneca LP.


Disclosure Policy
All relevant conflicts of interest have been mitigated prior to
the commencement of the activity.


Faculty/Planner
DisclosuresCo-Chair/Planner
Jonathan Corren, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Regeneron
Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.
Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and
Sanofi.


Co-Chair/Planner
Mario Castro, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead
Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.;
Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva
Pharmaceuticals USA, Inc.
Grant/Research Support from American Lung Association (ALA);
AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK;
National Institutes of Health (NIH); Novartis Pharmaceuticals
Corporation; Patient-Centered Outcomes Research Institute
(PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co.,
Ltd; and Theravance Biopharma.
Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron
Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals
USA, Inc.
Stock Shareholder in Aer Therapeutics.


Planning Committee and Reviewer
DisclosuresPlanners, independent reviewers, and
staff of PVI, PeerView Institute for Medical Education, do not
have any relevant financial relationships related to this CE
activity unless listed below.